Previous Close | 52.48 |
1-Year Change | 47.5% |
6-Months Change | 8.54% |
3-Months Change | 10.9% |
Moving Avg (50d) | 44.918 |
Moving Avg (200d) | 46.789 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.5B |
Beta (3-Years) | 1.61 |
Revenue Growth (ttm) | 16.3% |
Net Profit Margin (ttm) | -5.54% |
Return On Assets (ttm) | -3.22% |
EPS (ttm) | -0.22 |
PE Ratio (ttm) | -238.55 |
Dividend Yield | % |
Asset Description: | Vericel Corporation |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-19 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
56.115 | 54.397 | 53.252 | 51.534 | 48.671 | 45.808 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |